Clinical trials: IGA Glomerulonephritis
IgA Nephropathy, Lupus Nephritis
Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies
This is a Phase II trial assessing the safety and preliminary efficacy of daily APL-2 subcutaneous infusion administered for 16 weeks with a 6 month safety follow up, in patients with glomerulopathies
- Conditions
- IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, C3 Glomerulonephritis
- Trial name
- NCT03453619
- Testing
- APL-2
- Where
- 17 sites in United States
- Volunteers
- 21 people
- Sponsor
- Apellis Pharmaceuticals, Inc.
IgA Nephropathy
Efficacy and Safety of a Combination of Mycophenolate Mofetil and Corticosteroid in Advanced IgA Nephropathy
The purpose of this clinical study is to evaluate the efficacy and safety of that test group was administered with Mycophenolate Mofetil in combination with corticosteroid in patients with advanced IgA nephropathy.
- Trial name
- AIGA (NCT02981212)
- Testing
- Mycophenolate Mofetil, ACE inhibitor, Corticosteroid
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Yonsei University
Glomerulonephritis, IGA, Kidney Diseases
Trial of Plasma Exchange for Severe Crescentic IgA Nephropathy
Crescentic IgA nephropathy (CreIgAN) has a poor prognosis despite aggressive immunosuppressive therapy. The efficacy of plasma exchange (PE) in CreIgAN is not well defined.
- Conditions
- Glomerulonephritis, IGA, Kidney Diseases, Acute Renal Insufficiency, Rapidly Progressive Glomerulonephritis
- Trial name
- RESCUE (NCT02647255)
- Testing
- Plasma Exchange (PE), Methylprednisolone pulse
- Where
- 2 sites in China
- Volunteers
- 10 people
- Sponsor
- Peking University First Hospital
Treatment Resistant Nephrotic Syndrome
Treatment of Resistant Nephrotic Syndrome With ACTH Gel (ACTHAR)
This study will examine the safety and effectiveness of ACTHAR Gel, when used to treat 15 patients diagnosed with "treatment resistant nephrotic syndrome." Nephrotic syndrome is a group of symptoms that includes low levels of…
- Trial name
- NCT01129284
- Testing
- ACTHAR gel
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Columbia University
IgA Nephropathy
A Controlled Study of Uric Acid on the Progression of IgA Nephropathy
This prospective, randomized controlled study will evaluate the effect of uric acid on the progression of IgA nephropathy.
- Trial name
- NCT00793585
- Testing
- allopurinol, continue their usual therapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sun Yat-sen University
IgA Nephropathy (IgAN), Henoch Schönlein Purpura Nephritis
To Assess the Efficacy and Safety of Utilizing Galactose-deficient IgA1 Biomarker Changes to Guide Pathogenic IgA-targeted Therapeutic Strategies
The goal of this open-label, randomized study is to evaluate the efficacy and safety of the personalized treatment model in which Gd-IgA1 is dynamically monitored to guide medication adjustment in progressive IgAN patients…
- Trial name
- NCT07822100
- Testing
- Gd-IgA1 monitoring
- Where
- China
- Volunteers
- 374 people
- Sponsor
- Hong Zhang
IgA Nephropathy (IgAN)
Exploring the Brain - Gut Microbiota - Kidney Interactive Damage Mechanisms Underlying Cognitive Decline in Patients With IgA Nephropathy Using Ultra-high Field Magnetic Resonance Imaging
IgA nephropathy (IgAN) is the most common primary glomerular disease worldwide. Its progression is often accompanied by cognitive decline, manifesting as multi-dimensional cognitive deficits in areas such as memory, attention…
- Trial name
- NCT07617402
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Tang-Du Hospital
IgAN, C3G
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
This Phase 2 study is designed to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in adults with complement-mediated kidney diseases.
- Conditions
- IgAN, C3G, Complement-mediated Kidney Disease, IgA Nephropathy (IgAN)
- Trial name
- NCT06989359
- Testing
- ADX-038 Dose Level 2, ADX-038 Dose Level 1
- Where
- 38 sites in United States, Australia and 6 more
- Volunteers
- 45 people
- Sponsor
- ADARx Pharmaceuticals, Inc.
Glomerulonephritis, IGA, Hypertension
A Prospective Study of the Kidney Protective Effect of Aliskiren in Hypertensive Patients With IgA Nephropathy
The purpose of this study is to evaluate the effect of aliskiren, a novel direct rennin inhibitor, on renal function and progress of renal disease in hypertensive patients with IgA nephropathy.
- Trial name
- NCT01184599
- Testing
- aliskiren
- Where
- 4 sites in Japan
- Volunteers
- 30 people
- Sponsor
- Kagawa University
Immunoglobulin A Nephropathy
Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)
To Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects with Primary Immunoglobulin A Nephropathy
- Trial name
- NCT05248646
- Testing
- Sibeprenlimab 400 mg
- Where
- 308 sites in United States, Argentina and 29 more
- Volunteers
- 530 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Proteinuria
Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With Proteinuria
The primary objective of this study is to assess the impact of proteinuria on the pharmacokinetic (PK) of a single dose of ALXN1720 in participants with proteinuria.
- Trial name
- NCT05314231
- Testing
- ALXN1720
- Where
- 2 sites in South Korea
- Volunteers
- 13 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
IgA Nephropathy
SodiUm Restriction by Behavioral Intervention
The aim of this study is to evaluate the effects and efficacy of dietary sodium restriction by mean of a new healthcare approach in patients with immunoglobulin A nephropathy.
- Trial name
- SURBI (NCT04805047)
- Testing
- education and monitoring
- Where
- China
- Volunteers
- 142 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Lupus Nephritis, Immunoglobulin A Nephropathy
An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases
The goal of this clinical study is to evaluate multiple dose levels of povetacicept in adults with immunoglobulin A (IgA) nephropathy (IgAN), primary membranous nephropathy (pMN), lupus-related kidney disease (lupus nephritis …
- Conditions
- Lupus Nephritis, Immunoglobulin A Nephropathy, Membranous Nephropathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Trial name
- RUBY-3 (NCT05732402)
- Testing
- Povetacicept
- Where
- 30 sites in United States, Australia and 2 more
- Volunteers
- 72 people
- Sponsor
- Alpine Immune Sciences, Inc.
IgA Nephropathy
Efficacy and Safety of Mycophenolate Mofetil in Refractory IgA Nephropathy
This study is testing whether a medicine called mycophenolate mofetil (MMF) works better than the usual treatment for people whose kidney disease, called IgA nephropathy, has not improved with standard care.
- Trial name
- NCT07785128
- Testing
- Mycophenolate Mofetil (MMF), Prednisolon
- Where
- 3 sites in Bangladesh
- Volunteers
- 104 people
- Sponsor
- Shaheed Suhrawardy Medical College and Hospital
Healthy Volunteers
A Phase 1 Study of CLYM116 in Normal Healthy Volunteers
This Phase 1, first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of CLYM116 in healthy volunteers.
- Trial name
- NCT07248865
- Testing
- CLYM116
- Where
- Australia
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Climb Bio, Inc.
IgA Nephropathy
A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy.
This study will evaluate the efficacy and safety of HR19042 capsules compared to matching placebo for the treatment of primary IgA nephropathy, and explore the optimal dose for the treatment.
- Trial name
- NCT05016323
- Testing
- HR19042 Capsules
- Where
- China
- Volunteers
- 316 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
IgA Nephropathy
Study of BHV-1400 in IgA Nephropathy
The purpose of this study is to determine if BHV-1400 is a safe and tolerable treatment in participants with IgA Nephropathy (IgAN).
- Trial name
- NCT07054684
- Testing
- BHV-1400
- Where
- 15 sites in United States, United Kingdom
- Volunteers
- 20 people
- Sponsor
- Biohaven Therapeutics Ltd.
Kidney Disease, Glomerulonephritis
A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy
This study will have two parts. The main aims are to: check the side effects from mezagitamab. check for long-term side effects from mezagitamab.
- Trial name
- NCT05174221
- Testing
- Mezagitamab
- Where
- 26 sites in United States, Australia and 9 more
- Volunteers
- 17 people
- Sponsor
- Takeda
Autoimmune Diseases, SLE - Systemic Lupus Erythematosus
RD06-05 Universal CD19/BCMA CAR-T for Refractory Pediatric Autoimmune Diseases
This is a single-arm, open-label, phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of RD06-05, a universal CD19/BCMA dual-targeting chimeric antigen receptor T-cell…
- Conditions
- Autoimmune Diseases, SLE - Systemic Lupus Erythematosus, SSc-Systemic Sclerosis, IIM- Idiopathic Inflammatory Myopathies
- Trial name
- NCT07674147
- Testing
- RD06-05 CART Cell Infusion
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
IgA Nephropathy (IgAN)
A Study to Evaluate the Long-Term Safety and Efficacy of HSK39297 Tablets in Primary IgA Nephropathy
This is a Phase II, multicenter, open-label study. Eligible subjects who have completed the HSK39297-202 study will be enrolled.Starting dose is 200 mg QD.Dose may be increased to 300 mg QD after 8-12 weeks of stable 200 mg QD…
- Trial name
- NCT07616700
- Testing
- HSK39297 200mgQD, HSK39297 300mgQD
- Where
- 2 sites in China
- Volunteers
- 73 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.